Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

dc.contributor.author	Bennouna, Jaafar
dc.contributor.author	Sastre, Javier
dc.contributor.author	Arnold, Dirk
dc.contributor.author	Osterlund, Pia
dc.contributor.author	Greil, Richard
dc.contributor.author	Cutsem, Eric Van
dc.contributor.author	Moos, Roger von
dc.contributor.author	Viéitez de Prado, José María
dc.contributor.author	Bouché, Olivier
dc.contributor.author	Borg, Christophe
dc.contributor.author	Steffens, Claus-Christoph
dc.contributor.author	Alonso Orduña, Vicente
dc.contributor.author	Schlichting, Christoph
dc.date.accessioned	2014-03-14T07:40:45Z
dc.date.available	2014-03-14T07:40:45Z
dc.date.issued	2013
dc.identifier.citation	Lancet Oncology, 14(1), p. 29-37 (2013); doi:10.1016/S1470-2045(12)70477-1
dc.identifier.issn	1470-2045
dc.identifier.uri	http://hdl.handle.net/10651/23678
dc.description.statementofresponsibility	Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J.M., Bouché, O., Borg, C., Steffens, C.-C., Alonso-Orduña, V., Schlichting, C., Reyes-Rivera, I., Bendahmane, B., André, T., Kubicka, S.
dc.format.extent	p. 29-37
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartof	Lancet Oncology
dc.rights	© Elsevier
dc.source	WOS
dc.title	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
dc.type	journal article
dc.identifier.local	20140574
dc.identifier.doi	10.1016/S1470-2045(12)70477-1
dc.relation.publisherversion	http://dx.doi.org/10.1016/S1470-2045(12)70477-1

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.